awmsg logo



eltrombopag (Revolade®)


Reference No. 607

Publication date:
25/07/2014


Appraisal information

eltrombopag (Revolade®) 25 mg film-coated tablet
eltrombopag (Revolade®) 50 mg film-coated tablet


Company: Novartis Pharmaceuticals UK Ltd
BNF category: Nutrition and blood
NMG meeting date: 14/05/2014
AWMSG meeting date: 11/06/2014
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 1314
Ministerial ratification: 24/07/2014

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Eltrombopag (Revolade®) is recommended for use within NHS Wales in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon based therapy. This recommendation applies only in circumstances where the approved Patient Access Scheme is utilised.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download